401649-63-6

Basic information

• Product Name: 4-(TRIFLUOROMETHYL)-1,2-DIHYDRO-6-(4-METHOXYPHENYL)-2-THIOXOPYRIDINE-3-CARBONITRILE
• Synonyms: 4-(TRIFLUOROMETHYL)-1,2-DIHYDRO-6-(4-METHOXYPHENYL)-2-THIOXOPYRIDINE-3-CARBONITRILE;6-(4-METHOXYPHENYL)-2-THIOXO-4-(TRIFLUOROMETHYL)-1,2-DIHYDRO-3-PYRIDINECARBONITRILE;AKOS USSH-4110022;6-(4-methoxyphenyl)-2-sulfanylidene-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile
• CAS NO: 401649-63-6
• Molecular Formula: C₁₄H₉F₃N₂OS
• Molecular Weight: 310.29
• Mol File: 401649-63-6.mol

Chemical Properties

• Melting Point: 215-217 °C(Solv: ethanol (64-17-5))
• Boiling Point: 354.2±52.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• PKA: 5.88±0.70(Predicted)
• CAS DataBase Reference: 4-(TRIFLUOROMETHYL)-1,2-DIHYDRO-6-(4-METHOXYPHENYL)-2-THIOXOPYRIDINE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROMETHYL)-1,2-DIHYDRO-6-(4-METHOXYPHENYL)-2-THIOXOPYRIDINE-3-CARBONITRILE(401649-63-6)
• EPA Substance Registry System: 4-(TRIFLUOROMETHYL)-1,2-DIHYDRO-6-(4-METHOXYPHENYL)-2-THIOXOPYRIDINE-3-CARBONITRILE(401649-63-6)

Safety Data

• Hazardous Substances Data: 401649-63-6(Hazardous Substances Data)

Upstream product

• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 7357-70-2 Cyanothioacetamide 
• 15191-68-1 4,4,4-trifluoro-1-(4-methoxyphenyl)-1,3-butanedione 

Downstream Products

• 1581726-09-1 C₂₀H₁₈F₃N₃O₃S 

Relevant articles and documents

Compound for targeted ubiquitination degradation of FoxM1 or pharmaceutically acceptable salt thereof, preparation method and application

The invention discloses a compound for targeted degradation of FoxM1 or a pharmaceutically acceptable salt thereof, a preparation method and application. The structure is shown as a general formula (I). Experimental results show that compared with a FoxM1 inhibitor FDI-6, the compound provided by the invention can effectively degrade a transcription factor FoxM1, especially a compound F-8, and shows relatively good anti-breast cancer activity in both cellular and animal levels.

Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors

Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[2,3-b]pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 μM, SI >30.3, 12b, EC50 = 3.5 μM, SI >28.6, 10l, EC50 = 3.9 μM, SI >25.6, 12o, EC 50 = 4.5 μM, SI >22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents.

3-Amino-6-aryl(or 6-heteroaryl)-4-R2-thieno[2,3-b]pyridin-2-carboxylic acid amides, pharmaceutical compositions comprising the said and their use as inhibitors of TNFalpha release

3-Amino-6-(hetero)aryl-thieno[2,3-b]pyridin-2-carboxylic acid amide derivatives (I) and their solvates, salts, prodrugs formulations, active metabolites or optionally tautomers are new. 3-Amino-6-(hetero)aryl-thieno[2,3-b]pyridin-2-carboxylic acid amide d

SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, SUBSTITUTED THIENO[2,3-D:4,5-D']DIPYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, SUBSTITUTED PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND SUBSTITUTED FURO[2,3-D:4,5-D']DIPYRIMIDINE-2,4(1 H,3H)-DIONES AN

The invention relates to novel pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=C-H, Y=S), thieno[2,3-d:4,5-d']dipyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=N, Y=S), in addition to pyrido[3',2':4,5]furo[3,2-d]pyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=C-H, Y=0) and furo[2,3-d:4,5-d']dipyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=N, Y=O) of general formulae 1a and 1b. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or tautomers thereof and physiologically compatible salts which can be produced therefrom and/or solvates thereof, in addition to the pharmaceutical use of said compounds, tautomers thereof, salts or solvates, as inhibitors of TNFa-release.